Senate Judiciary Members Admit Drug Pricing Bills Remain Stalled
At a Senate Judiciary Committee hearing, lawmakers including Sen. John Kennedy (R-La.) acknowledged that Congress has failed to advance drug pricing reform despite Republican control, with Kennedy calling the inaction "zero, zilch, nada." Chairman Chuck Grassley (R-Iowa) noted the committee advanced six bipartisan bills last year targeting drugmaker and PBM practices, but only one, the Affordable Prescriptions for Patients Act, reached the Senate floor; Grassley cited a crowded calendar and industry pushback as likely factors. Witnesses, including Patients for Affordable Drugs Now CEO Merith Basey and Cost Plus Drug Company CEO Alex Oshmyansky, testified that the bills should pass as a package to address patent abuses like product hopping and patent thickets, and that PBM consolidation among CVS Caremark, Express Scripts and OptumRx drives high costs and limits competition.